In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...
In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...
Supermodels, singers, and diabetics are all wearing it. Jake Leach, Dexcom CEO, says these sensors are the future.
Hosted on MSN
Morgan Stanley upgrades DexCom (DXCM), cites undervalued recovery and G7 margin potential
DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback